# SMP-656 for HER2-Positive Advanced Breast Cancer

> **NCT07726342** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chengdu SciMount Pharmatech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer (LABC)

## Interventions

- **DRUG:** SMP-656 Injection
- **DRUG:** SMP-656 Injection

## Key facts

- **NCT ID:** NCT07726342
- **Lead sponsor:** Chengdu SciMount Pharmatech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-16
- **Primary completion:** 2027-07-07
- **Final completion:** 2027-10-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726342, "SMP-656 for HER2-Positive Advanced Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*